Drug Trial Radar · NCT00625898
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Last checked: Nov 19, 2026Latest source record: Sep 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3,509
Actual
Start
Apr 2008
Primary completion
Jun 2013
Study completion Jul 2014
Sponsor
- Lead sponsor
- NSABP Foundation IncResearch network
- Sponsor type
- Research network
- Collaborators
- Cancer International Research Group (CIRG); Hoffmann-La Roche; Genentech, Inc.
- First posted
- Feb 29, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Conditions
- Breast Cancer
Interventions
DocetaxelDrug
75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B 100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B
TrastuzumabDrug
First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B
CarboplatinDrug
6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
BevacizumabDrug
15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B 15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B
5-FluorouracilDrug
600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
EpirubicinDrug
90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
CyclophosphamideDrug
600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-free Survival (IDFS)Time frame: up to 10 years
Locations
649 sites in 40 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Clearview Cancer Institute-Decatur
Decatur, Alabama
Clearview Cancer Institute
Huntsville, Alabama
Clearview Cancer Institute- Huntsville
Huntsville, Alabama
Northern Arizona Hematology & Onclogy Associates
Flagstaff, Arizona
Northern Arizona Hematology & Oncology Associates
Sedona, Arizona
Central Hematology/Oncology Medical Group, Inc.
Alhambra, California
Comprehensive Blood and Cancer Center
Bakersfield, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Providence Saint Joseph Medical Center
Burbank, California
Hematology-Encinitas
Encinitas, California
Scripps Clinic Encinitas
Encinitas, California
Kaiser Permanente-Fontana
Fontana, California
St. Jude Heritage Healthcare
Fullerton, California
Breastlink Medical Group, Inc
Hawthorne, California
Pacific Shores Medical Group
Huntington Beach, California
Kaiser Permanente-Irvine
Irvine, California
Hematology-La Jolla
La Jolla, California
Sabina R. Wallach, MD., AMC
La Jolla, California
Scripps Cancer Center-San Diego
La Jolla, California
Antelope Valley Cancer Center
Lancaster, California
Kaiser Permanente-Sunset
Los Angeles, California
Kaiser Permanente-West Los Angeles
Los Angeles, California
Kaiser Permanente-Oakland
Oakland, California
North County Oncology Medical Clinic, Inc.
Oceanside, California
Kaiser Permanente-Panorama City
Panorama City, California
Kaiser Permanente-Orange County
Panorama City, California
Wilshire Oncology Medical Group
Pasadena, California
Cancer Care Associates Medical Group, Inc.
Redondo Beach, California
Kaiser Permanente-Riverside
Riverside, California
Kaiser Permanente-Roseville
Roseville, California
Sutter Roseville Medical Center
Roseville, California
Kaiser Permanente-Sacramento
Roseville, California
Sutter Medical Center
Sacramento, California
Sutter Medical Group
Sacramento, California
Peter T. Reissman, MD, Inc
San Diego, California
William Stanton, MD, Inc
San Diego, California
Kaiser Permanente-San Diego
San Diego, California
Sharp Rees-Stealy
San Diego, California
Showing 40 of 649 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.